Simcere Pharmaceutical Group Limited (SEHK: 2096)
Health Care · Pharmaceuticals · CN
HK$12.08
-0.49% today · -18.4% 1Y
Simcere Pharmaceutical Group Limited (SEHK: 2096) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.96B and employs 7,038 people.
Over the last twelve months the share price has lost 18.4%, trading between 9.07 and 15.08.
Tweenvest scores Simcere Pharmaceutical Group Limited across four factors: quality 77/100, value 58/100, growth 67/100, dividend 54/100. Its strongest factor is quality.
2096 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.96B
- Revenue (TTM)
- $1.28B
- P/E
- 17.19
- EPS
- 0.61
- Dividend yield
- 1.74%
- Beta (5Y)
- 0.73
- 52-week high
- HK$15.08
- 52-week low
- HK$9.07
- Avg volume (3M)
- —
- Shares outstanding
- 2.57B
- Employees
- 7,038
- Next earnings
- —
About Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
- ISIN
- HK0000658531
- Founded
- 1995
- Listed since
- Oct 27, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.